Company Encyclopedia
View More
name
Merck
MRK.US
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.
4.513 T
MRK.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking35/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE39.51%A
    • Profit Margin29.63%A
    • Gross Margin78.32%A
  • Growth ScoreC
    • Revenue YoY1.68%C
    • Net Profit YoY56.68%B
    • Total Assets YoY10.22%B
    • Net Assets YoY16.49%A
  • Cash ScoreC
    • Cash Flow Margin337.48%C
    • OCF YoY1.68%C
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreD
    • Gearing Ratio59.93%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

    Vaccine makers, including Merck and GSK, are concerned about a U.S. advisory panel's decision to stop recommending hepatitis B vaccines for all newborns. Merck warns this could increase risks of chronic infection and liver cancer. The panel now advises vaccination only for infants of mothers who test positive for hepatitis B. Merck and GSK shares fell slightly, while Sanofi shares rose. The decision has sparked criticism from public health experts and organizations.

    Reuters·
    UK
    GSK
    0.00%
    US
    GSK
    -0.33%
    US
    MRK
    -1.16%
    Reuters·
    UK
    GSK
    0.00%
    US
    GSK
    -0.33%
    US
    MRK
    -1.16%

    M Holdings Securities Inc. Boosts Stake in Merck & Co., Inc. $MRK

    M Holdings Securities Inc. increased its stake in Merck & Co., Inc. by 55.7% in Q2, owning 47,025 shares valued at $3.72 million. Other investors also adjusted their holdings. Merck's stock opened at $100.85, with a market cap of $250.31 billion. The company reported Q3 earnings of $2.58 per share, surpassing estimates, and increased its quarterly dividend to $0.85 per share.

    Market Beat·
    US
    MRK
    -1.16%
    Market Beat·
    US
    MRK
    -1.16%

    Health Care Down Sharply on Rotation to Rate-Sensitive Sectors -- Health Care Roundup

    Health-care stocks fell sharply as traders shifted to rate-sensitive sectors. Halozyme secured a preliminary injunction against Merck & Co. in a patent dispute over Keytruda in Germany. The Trump administration's biomedical innovation goals face challenges within the FDA, amid infighting and staff turnover influenced by Robert F. Kennedy Jr.'s policy changes.

    marketscreener·
    US
    MRK
    -1.16%
    US
    HALO
    +0.60%
    marketscreener·
    US
    MRK
    -1.16%
    US
    HALO
    +0.60%

    Merck Raises $8 Billion in Multi-Tranche Notes Offering

    Merck & Co., Inc. has raised $8 billion through a multi-tranche notes offering, including various debt instruments with maturities ranging from 2029 to 2065. The offering closed on December 4, 2025, under the company's shelf registration statement filed with the SEC. This capital raising effort involves several series of notes with varying interest rates and maturities.

    Reuters·
    US
    MRK
    -1.16%
    Reuters·
    US
    MRK
    -1.16%

    Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC In Germany

    Dec 4 (Reuters) - Halozyme Therapeutics Inc:HALOZYME WINS PRELIMINARY INJUNCTION AGAINST MERCK’S KEYTRUDA SC IN GERMANYHALOZYME THERAPEUTICS: AS CONSEQUENCE OF INJUNCTION MERCK’S LAUNCH ACTIVITIES FOR KEYTRUDA SC IN GERMANY WITHIN SCOPE OF ORDER MUST BE HALTEDHALOZYME THERAPEUTICS: OUTCOME OF THE INFRINGEMENT LAWSUIT AGAINST MERCK WILL NOT IMPACT ENHANZEHALOZYME THERAPEUTICS INC - IV VERSION OF KEYTRUDA REMAINS AVAILABLE TO PATIENTS Source text: Further company coverage:

    Reuters·
    US
    HALO
    +0.60%
    Reuters·
    US
    HALO
    +0.60%
    Posts
    View More

    $Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals Inc.（RXRX）Weekly Report (2025.11.22-11.29) The extent of your achievements can largely be seen from how much pain you can endure...

    Some green names holding up this morning. $Ondas(ONDS.US) $Medtronic(MDT.US) $Freeport Mcmoran(FCX.US) $Gorilla Tech(GRRR.US) $Merck(MRK.US) $Loandepot(LDI.US) $Strategy(MSTR.US) $Us Antimony(UAMY.US...............

    The Nasdaq Composite Index fell 2.7%, with a cumulative annual decline of 10.3%. - The S&P 500 Index dropped 1.97%, with a cumulative annual decline of 5.1%. - The Dow Jones Index declined 1.69%, with...

    © 2025 Longbridge｜Disclaimer